Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

TREM-1; is It a Pivotal Target for Cardiovascular Diseases?

Version 1 : Received: 2 September 2018 / Approved: 3 September 2018 / Online: 3 September 2018 (14:50:17 CEST)

How to cite: Kouassi, K.T.; Gunasekar, P.; Agrawal, D.K.; Jadhav, G. TREM-1; is It a Pivotal Target for Cardiovascular Diseases?. Preprints 2018, 2018090040. Kouassi, K.T.; Gunasekar, P.; Agrawal, D.K.; Jadhav, G. TREM-1; is It a Pivotal Target for Cardiovascular Diseases?. Preprints 2018, 2018090040.


Cardiovascular Diseases (CVDs) are still menacing and killing adults worldwide, notwithstanding the tremendous effort, to decrease their related mortality and morbidity. Lately, a growing body of evidences indicated that inflammation plays a pivotal role in the pathogenesis and complications of CVDs. A receptor of the immunoglobulin superfamily, triggering receptor expressed on myeloid cells -1 (TREM-1) was shown to induce and to amplify the inflammation in both acute and chronic diseases pathogenesis and progression and hence it is one of the important factors that complicates CVDs. Thus, studies endeavored to investigate the role played by TREM-1 in CVDs with respect to their etiologies, complications and possible therapeutics. We examined here, for the first time, the most relevant studies regarding TREM-1 involvement in CVDs. We summarized the finding after critically analyzing them and made some suggestions for furtherance of the investigations with the aim to utilize TREM-1 and its pathways for diagnostic, management and prognosis of CVDs. Overall, TREM-1 was found to be involved in the pathogenesis of acute and chronic cardiovascular conditions like Acute myocardial infraction (AMI) and atherosclerosis as well. Although most therapeutic approaches are yet to be elucidated, present research outcome displays a promising future to utilize TREM-1 pathway as potential target to understand and manage CVDs.


Triggering receptor expressed on myeloid cells, DNAX-activating protein 12, cardiovascular diseases, atherosclerosis, coronary arteries diseases, acute myocardial infract, endocarditis


Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Comments (1)

Comment 1
Received: 3 September 2018
Commenter: John bright
The commenter has declared there is no conflict of interests.
Comment: It is indeed a great review.
New field of study and TREM-1 seems to be interesting target.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.